Ibrutinib-associated necrotic nasal lesion and pulmonary infiltrates.
| Autor: | Saling C; Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA., Feller F; Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, USA., Vikram HR; Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA vikram.hr@mayo.edu. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | BMJ case reports [BMJ Case Rep] 2021 Jan 19; Vol. 14 (1). Date of Electronic Publication: 2021 Jan 19. |
| DOI: | 10.1136/bcr-2020-237085 |
| Abstrakt: | Herein, we report a case of a 68-year-old woman receiving ibrutinib for chronic lymphocytic leukaemia, who presented with septic shock and a progressive necrotic lesion on her nose. Surgical pathology of the nasal lesion revealed evidence of tissue necrosis, and both tissue and blood culture grew Pseudomonas aeruginosa A diagnosis of ecthyma gangrenosum was made. Additional investigations also led to the discovery of invasive pulmonary aspergillosis. To our knowledge, this is the first case of ecthyma gangrenosum secondary to Pseudomonas sepsis and concurrent invasive pulmonary aspergillosis associated with ibrutinib use. Competing Interests: Competing interests: None declared. (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|